Lattice Biologics Ltd. (LBLTF)

OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Dec 3, 2025
Market Cap128.00
Revenue (ttm)1.56M
Net Income (ttm)-951.65K
Shares Out128.22M
EPS (ttm)-0.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume25,000
Average Volume14,628
Open0.0000
Previous Close0.0000
Day's Range0.0000 - 0.0000
52-Week Range0.0000 - 0.0000
Beta0.92
RSI41.21
Earnings Daten/a

About Lattice Biologics

Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologics products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. It develops acellular demineralized bone scaffold, a human cortical bone demineralized that are used in various applications in orthopedic, neurological, trauma, oral/maxillofacial, and reconstructive procedures; and acellular dermal matrix that provides a natural collagen tissue scaffold that promotes cellular ingrowth, tissue vascularization,... [Read more]

Sector Healthcare
Country Canada
Stock Exchange OTCMKTS
Ticker Symbol LBLTF
Full Company Profile

Financial Performance

In 2020, Lattice Biologics's revenue was $2.46 million, an increase of 12.60% compared to the previous year's $2.19 million. Losses were -$1.48 million, 46.5% more than in 2019.

Financial Statements

News

Lattice Biologics Ltd. Reports Second Quarter 2021 Results and Resumes Trading

ISLAND PARK, Id.--(BUSINESS WIRE)--Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for Q2 2021. Highlights of Six Months Ended Mar...

4 years ago - Business Wire

Lattice Biologics Reorganizes to Focus on Psychedelics and Cannabis Therapies

BELGRADE, Mont.--(BUSINESS WIRE)--Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announced today that the Company will change its business strategy to focus ...

5 years ago - Business Wire

Lattice Biologics Ltd. Announces Resignation of Director

BELGRADE, Mont.--(BUSINESS WIRE)--Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces that Mr. Donald McInnes has resigned as a director of the Company,...

5 years ago - Business Wire

Lattice Biologics Ltd. Reports First Quarter 2021 Highlights

BELGRADE, Mont.--(BUSINESS WIRE)--Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for Q1 2021. Highlights of Three Months Ended De...

5 years ago - Business Wire